Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Helen F. Graham Cancer Center
& Research Institute

Endobronchial Lung Volume Reduction

Nonsurgical valve placement for patients with severe COPD / emphysema

With endobronchial lung volume reduction a newly FDA-approved breakthrough nonsurgical valve placement procedure for severe emphysema available in Delaware only at ChristianaCare — tiny, one-way valves block off diseased parts of the lung so healthier lung tissue can expand and take in more air. Clinical studies show that almost immediately patients are able to:

  • Breathe easier.
  • Be more active and energetic.
  • Experience less shortness of breath.
  • Enjoy a significantly improved quality of life compared to untreated patients. 

No incision. No pain. Immediate relief.

Endobronchial valves help patients take their first full breath in years almost immediately after the procedure. Within a few days, they are back to doing everyday tasks with ease.

Here’s how it works:

In a procedure known as bronchoscopy that takes about 30 minutes under general anesthesia (where the patient is completely asleep), tiny, FDA-approved valves are guided through a small tube from the nose or mouth to the lungs. No incision is needed.

A tiny camera also guided through the tube helps the interventional pulmonologist place, on average, 4 valves in the airways to block off diseased parts of the lung.  The valves reduce hyperinflation, preventing air from becoming trapped in the diseased area of the lung and allowing healthier parts of the lung to take in more air.  

Most patients report immediate relief and easier breathing as soon as they wake up from the procedure. Patients stay in the hospital for approximately 3-5 days for observation following the valve placement.

After the procedure, patients continue to use the medicines prescribed by their doctor for emphysema. Pulmonary rehabilitation helps patients achieve maximum benefit from the valve procedure.

Endobronchial lung volume reduction may be right for you if you:

  • Have known or suspected severe emphysema (a form of chronic obstructive pulmonary disease, or COPD) and hyperinflation (when air gets trapped in diseased parts of the lung) with a higher degree of obstruction of the airways (FEB1 <50% predicted).
  • Are breathless despite taking medications or using supplemental oxygen.
  • Cannot have surgery due to other medical conditions.
  • Do not currently have a severe heart condition.
  • Are not a current smoker.

To learn more, talk to your primary care provider or pulmonologist, or call ChristianaCare’s Interventional Pulmonology team at 302-623-4530.

A simple diagnostic workup that includes pulmonary function testing, a computed tomography (CT) scan and other testing will help to determine if the procedure is right for you. 

Thoracic Surgery & Interventional Pulmonology
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4530